Bristol-Myers Squibb Provides Update on Pending Merger with Celgene
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Spark Therapeutics (ONCE) Trades Lower in Sympathy with Celgene (CELG)
June 24, 2019 10:35 AM EDTSpark Therapeutics (NASDAQ: ONCE) traded lower Monday in sympathy with Bristol-Myers Squibb (NYSE: BMY) and Celgene (NASDAQ: CELG) after they announced plans to divest Otezla to get U.S. regulators to approve their deal.
Spark Therapeutics previously announced an agreement to merge with Roche.
... More